Composite Vaccine Adjuvant Formulations With Lower Reactogenicity
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing adjuvants for vaccines are limited in their ability to stimulate a targeted immune response without causing adverse effects, and there is a need for an adjuvant formulation that can elicit both cell-mediated and humoral immune responses across a wide range of antigens while minimizing side effects and formulation difficulties.
Innovation Solution
Adjuvant formulations comprising a combination of saponin, sterol, quaternary ammonium compound, and optionally a polymer or glycolipid, such as Quil A, cholesterol, and DDA or polyacrylic acid, which are configured to elicit potent immune responses and reduce reactogenicity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If traditional adjuvants are used to enhance immune response, then immune stimulation is improved, but toxic side effects and reactogenicity increase
Solution Approach 1:
The patent combines multiple adjuvant components (saponin, sterol, quaternary ammonium compound, polymer) into a composite formulation that achieves synergistic immune stimulation while reducing individual component toxicity. This composite approach allows the formulation to elicit both cell-mediated and humoral immune responses without the severe reactogenicity associated with traditional single-component adjuvants.
Solution Approach 2:
The patent modifies key parameters of adjuvant formulations by controlling the concentration ratios and molecular characteristics of components. Specifically, it adjusts the saponin-to-sterol ratio, molecular weight of polymers, and charge density of quaternary ammonium compounds to optimize immune response while minimizing toxic effects. This parameter optimization enables effective adjuvanticity at lower, safer concentrations.
2Ease of manufacture
If homogeneous preparations of pathological microorganisms are used as antigens, then manufacturing is simplified, but immune response is poor
Solution Approach 1:
The patent creates a composite adjuvant system that works effectively with purified protein subunit antigens, replacing the need for crude microbial preparations. The combination of saponin, sterol, quaternary ammonium compound, and polymer provides multifaceted immune stimulation that compensates for the lower immunogenicity of homogeneous antigen preparations, thereby maintaining manufacturing simplicity while improving immune response quality.
3Reliability
If purified protein subunits are used as antigens, then vaccine purity is improved, but production cost increases
Solution Approach 1:
The patent optimizes the dosage parameters of the adjuvant formulation to achieve effective immune response with smaller amounts of purified antigen. By adjusting the concentration and composition of adjuvant components, the formulation enhances antigen potency, allowing reduced antigen dosage and consequently lower production costs while maintaining high vaccine purity standards.
4Reliability
If adjuvants are added to increase immune response magnitude, then immune stimulation is improved, but injection site reactions increase
Solution Approach 1:
The patent employs a composite adjuvant formulation where each component contributes a specific function: saponin for membrane interaction and immune cell activation, sterol for stability and modulated release, quaternary ammonium compound for enhanced antigen presentation, and polymer for sustained delivery. This distributed functionality achieves high immune response magnitude while each component operates at lower, less reactogenic concentrations than single-component adjuvants would require.
Data Source
AI summary
This invention relates to adjuvant formulations comprising various combinations of triterpenoids, sterols, immunomodulators, polymers, and Th2 stimulators; methods for making the adjuvant compositions; and the use of the adjuvant formulations in immunogenic and vaccine compositions with different antigens. This invention further relates to the use of the formulations in the treatment of animals.